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A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the
epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated
hepatic enzyme levels that resulted in the discontinuation of gefitinib. Gefitinib was reintroduced with an intermittent treatment
schedule after the transaminase levels normalized, but the patient’s enzyme levels rose again, and the cancer progressed. Gefitinib
was eventually replaced with erlotinib. There was stable disease for 7 weeks without any signs of liver toxicity. Thus, erlotinib may
be a beneficial and well-tolerated treatment option for patients with gefitinib-related hepatotoxicity.
1. Introduction
Recent reports suggest that epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) induce an early and
dramatic response in patients with non-small-cell lung can-
cer (NSCLC) [1]. Subgroup analyses revealed that respon-
siveness to EGFR-TKI is more frequently observed in female
nonsmokers with adenocarcinoma and that responsiveness is
associated with specific gain-of-function mutations at exons
18, 19, and 21 of the EGFR gene, which are found in 10% of
NSCLC cases in Europe and the United States and in 26% of
NSCLC cases in East Asia [2].
Gefitinib is generally reported to be well tolerated, and
the most common side effects consist of mild to moderate
gastrointestinal disturbances and skin reactions [3–6]. Most
patients had no deterioration in hepatic function during the
trial, and occurrences of elevated levels of transaminases were
generally grade 1, as assessed by the National Cancer Institute
Common Toxicity Criteria version 2.0 grading system, and
asymptomatic [3]. However, gefitinib-related hepatotoxicity
was a dose-limiting toxicity in phase 1 studies [7–10]. Re-
cently, the incidence of grade 3/4 liver transaminase levels, as
assessed by the Common Terminology Criteria for Adverse
Events (CTCAEs version 3.0) grading system proposed by
the National Cancer Institute, was reported to be significantly
higher with gefitinib than with carboplatin plus paclitaxel in
a phase 3 study (9.4% versus 1.0%, resp.) [5]. Furthermore,
in the Iressa Dose Evaluation in Advanced Lung Cancer
(IDEAL 1) trial, 2% of patients receiving gefitinib alone at
a dose of 250 mg once daily developed grade 3 or 4 elevations
of hepatic enzymes that necessitated the cessation of treat-
ment [3]. Therefore, an effective treatment method needs
to be developed for patients for whom gefitinib has been
discontinued because of severe hepatotoxicity irrespective of
their response to gefitinib.
The present study describes the case of a 73-year-old
Japanese man who was histologically diagnosed with lung
adenocarcinoma harboring an exon 19 deletion in the epi-
dermal growth factor receptor and who developed a substan-
tial elevation of hepatic enzymes during gefitinib treatment.
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Following the case presentation, we discuss the treatment
strategy for gefitinib-related hepatotoxicity through a review
of pertinent reports.
2. Case Presentation
A 73-year-old Japanese man with a 17 pack-year smok-
ing history was diagnosed with lung adenocarcinoma and
underwent a right lower lobectomy in February 2004. The
lung adenocarcinoma was pathologically characterized as
T2N1M0, stage IIB, according to the TNM classification
of the International Union Against Cancer (UICC) [11].
Twenty months later, the tumor had relapsed in the pleura
and lymph node, but the relapse was asymptomatic, so
the patient was routinely monitored. In February 2008, the
patient developed bone and brain metastasis, and he received
gamma knife radiation and first-line chemotherapy with
carboplatin (area under the plasma concentration time curve
(AUC) of 5, day 1) and gemcitabine (1000 mg/m2, days 1
and 8). However, this chemotherapy was discontinued after
two cycles due to the continued development of tumor.
The patient developed a lumbar backache, and magnetic
resonance imaging scans of the thoracolumbar vertebrae
showed bone metastases at the fourth and tenth thoracic
vertebrae. He underwent radiation therapy (30 Gy/10 Fr) for
the bone metastases and subsequently received second-line
treatment with gefitinib (250 mg/day) in December 2008, as
mutation analysis of a lung cancer specimen obtained from
the right lower lobectomy detected the presence of an exon
19 deletion in EGFR. The tumors exhibited some reduction
in size, and the patient had radiological stable disease, neither
a partial response nor progressive disease, according to the
Response Evaluation Criteria in Solid Tumours (RECIST).
After 6 weeks of gefitinib treatment, the patient devel-
oped substantially elevated hepatic enzymes (AST 386 IU/L,
range, 13–31; ALT 801 IU/L, range, 8–34), and the gefitinib
treatment was discontinued. A chest X-ray demonstrated
mass opacity at the right hilar area, and a computed tomog-
raphy (CT) scan of the chest and the abdomen showed
mass opacity involving the right hilar lymph node without
any signs of liver metastasis (Figure 1). A baseline blood
test revealed that the electrolyte levels and renal function
were normal. The number of eosinophils, which increase in
allergic reaction, was also within normal limit. The patient
had no previous history of liver disease, excess alcohol intake,
hepatitis, or liver metastasis. The patient did have a history
of diabetes mellitus that was controlled by oral medication
and prostate cancer that was well controlled by periodic
hormonal therapy with leuprorelin. He was not routinely
prescribed a medicine other than these medications. In addi-
tion, he did not take any supplement. Gefitinib treatment was
reintroduced with an intermittent schedule after the patient’s
transaminase levels normalized; however, the enzyme levels
rose again when 250 mg of gefitinib was administered every
two days (Figure 2). The lung cancer progressed after two
weeks of treatment with 250 mg of gefitinib administered
every three days. Therefore, the treatment was switched to
erlotinib (150 mg once daily) 159 days after the initiation
Figure 1: Computed tomography (CT) scan of the chest shows a
mass opacity involving the right hilar lymph node.
of gefitinib, and the tumor decreased in size, as determined
by chest X-ray (Figure 2). Although the patient experienced
grade 2 fatigue and nausea, as assessed by CTCAE ver.
3.0, he recovered after the treatment was suspended and
then reinitiated at a reduced dose of 100 mg once daily.
Tumor control and normal levels of liver enzymes were
maintained, but the tumor gradually grew larger 7 weeks
after the administration of erlotinib. Erlotinib was subse-
quently discontinued, and chemotherapy with pemetrexed
(500 mg/m2) was administered. We had stable disease during
pemetrexed treatment. The patient then received palliative
care combined with steroids, and he survived for 24 months
after the initiation of erlotinib therapy. The patient died as a
result of complications from the malignancy in May 2011.
3. Discussion
The management of gefitinib-related hepatotoxicity provides
great value to patients, especially those patients with lung
adenocarcinoma harboring an EGFR mutation who are
expected to respond to EGFR-TKI. There are two strategies
to overcome gefitinib-related hepatotoxicity: (1) an intermit-
tent schedule of gefitinib administration (once every 2 or 5
days) and (2) the use of erlotinib instead of gefitinib. Both
strategies were used in the treatment of the patient reported
herein.
The reintroduction of gefitinib administration at the
same dose after its discontinuation due to hepatotoxicity has
been reported in two cases and resulted in the discon-
tinuation of gefitinib treatment because of the repeated
elevation of serum transaminase levels [12, 13]. Tomisaki et
al. described a case in which gefitinib was reintroduction at
an intermittent schedule of every two days; this intermittent
schedule resulted in successful tumor control and reduced
toxicity, such as grade 3 skin trouble and rash [14]. This
alternate-day regimen is in widespread clinical use to control
the complications of gefitinib, although it is still unknown
whether this schedule confers a survival benefit. Seki et al.
reported that the intermittent administration of gefitinib
every 5 days yielded successful tumor control for 8 weeks and

















































Figure 2: The course of chest X-ray images and transaminase levels during gefitinib and erlotinib treatments.
reduced hepatotoxicity [15]. This strategy for intermittent
gefitinib dosing was based on data from the IDEAL 1 trial,
in which grade 1 to 4 elevations of transaminases were more
common in patients receiving a dose of 500 mg/day (24%)
than in patients receiving 250 mg/day (13%) [3]. In addition,
the maximum plasma concentration (Cmax) and the AUC
were dependent on the number of consecutive days gefitinib
was administered in two phase 1 trials [9, 10]; that is, 14
consecutive days dosing resulted in the Cmax and the AUC
2.3-fold and 4.0-fold higher than a single dose, respectively,
[9]. In our case, we first reintroduced gefitinib with an
intermittent treatment schedule of every two days and then
every three days; however, unlike the above-mentioned
cases, gefitinib did not yield reduced hepatotoxicity when
administered every two days and it did not yield tumor
control when administered every three days. Therefore, we
changed the medication from gefitinib to erlotinib.
Although gefitinib and erlotinib are similar anilinoquina-
zoline EGFR-TKIs, the incidence of grade 3/4 liver transam-
inase levels was reported to be higher with gefitinib than
with erlotinib in three phase 3 studies [16–18]. One of the
reasons why liver dysfunction is more frequent in gefitinib
group than in erlotinib group is thought to be the difference
between their metabolisms. Although they undergo extensive
metabolism, mainly via hepatic and intestinal cytochrome
P450 (CYP) 3A4, gefitinib is also metabolized via CYP 2D6,
whereas erlotinib is also metabolized via CYP 1A2 [19].
Therefore, the deletion or inactivation in the gene encoding
CYP2D6 might have caused gefitinib-related hepatotoxicity.
Furthermore, the standard dose of gefitinib (250 mg/day) is
lower than the maximal tolerated dose (MTD); however, the
approved daily dose of erlotinib (150 mg/day) is equal to
the MTD, because response and survival were not different
between 250 and 500 mg of gefitinib among two phase 2
trials [3, 20]. Thus, an erlotinib dosage close to the MTD
is considered to achieve more effective drug concentrations
when compared with gefitinib administered at an intermit-
tent schedule. That is why this change in medication worked
well for our patient, in terms of both reduced toxicity and
successful tumor control. In fact, successful treatment with
erlotinib after gefitinib-related severe hepatotoxicity has been
reported by Takeda et al. [21], although an intermittent
schedule of gefitinib was not used in their case (unlike that
in our case).
In conclusion, the present case illustrates helpful treat-
ment with erlotinib for a patient with gefitinib-related hepa-
totoxicity and lung adenocarcinoma refractory to an inter-
mittent schedule of administration. Erlotinib can be an
effective and well-tolerated treatment option for patients
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for whom gefitinib has been discontinued because of severe
hepatotoxicity irrespective of their response to gefitinib.
Conflict of Interests
The authors declare the absence of any potential conflict of
interests or financial interests which include supporting
grants.
References
[1] F. A. Shepherd, P. J. Rodrigues, T. Ciuleanu et al., “Erlotinib in
previously treated non-small-cell lung cancer,” New England
Journal of Medicine, vol. 353, no. 2, pp. 123–132, 2005.
[2] A. M. Ruppert, M. Beau-Faller, A. Neuville et al., “EGFR-
TKI and lung adenocarcinoma with CNS relapse: interest of
molecular follow-up,” European Respiratory Journal, vol. 33,
no. 2, pp. 436–440, 2009.
[3] M. Fukuoka, S. Yano, G. Giaccone et al., “Multi-institutional
randomized phase II trial of gefitinib for previously treated
patients with advanced non-small-cell lung cancer,” Journal of
Clinical Oncology, vol. 21, no. 12, pp. 2237–2246, 2003.
[4] E. S. Kim, V. Hirsh, T. S. Mok et al., “Gefitinib versus docetaxel
in previously treated non-small-cell lung cancer (INTEREST):
a randomised phase III trial,” The Lancet, vol. 372, no. 9652,
pp. 1809–1818, 2008.
[5] T. S. Mok, Y. L. Wu, S. Thongprasert et al., “Gefitinib or
carboplatin-paclitaxel in pulmonary adenocarcinoma,” New
England Journal of Medicine, vol. 361, no. 10, pp. 947–957,
2009.
[6] N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best
supportive care in previously treated patients with refractory
advanced non-small-cell lung cancer: results from a random-
ised, placebo-controlled, multicentre study (Iressa survival
evaluation in lung cancer),” The Lancet, vol. 366, no. 9496, pp.
1527–1537, 2005.
[7] J. Baselga, D. Rischin, M. Ranson et al., “Phase I safety, phar-
macokinetic, and pharmacodynamic trial of ZD1839, a selec-
tive oral epidermal growth factor receptor tyrosine kinase
inhibitor, in patients with five selected solid tumor types,”
Journal of Clinical Oncology, vol. 20, no. 21, pp. 4292–4302,
2002.
[8] R. S. Herbst, A. M. Maddox, M. L. Rothenberg et al., “Selec-
tive oral epidermal growth factor receptor tyrosine kinase
inhibitor ZD1839 is generally well-tolerated and has activity
in non-small-cell lung cancer and other solid tumors: results
of a phase I trial,” Journal of Clinical Oncology, vol. 20, no. 18,
pp. 3815–3825, 2002.
[9] K. Nakagawa, T. Tamura, S. Negoro et al., “Phase I pharma-
cokinetic trial of the selective oral epidermal growth factor
receptor tyrosine kinase inhibitor gefitinib (“Iressa”, ZD1839)
in Japanese patients with solid malignant tumors,” Annals of
Oncology, vol. 14, no. 6, pp. 922–930, 2003.
[10] M. Ranson, L. A. Hammond, D. Ferry et al., “ZD1839, a
selective oral epidermal growth factor receptor-tyrosine kinase
inhibitor, is well tolerated and active in patients with solid,
malignant tumors: results of a phase I trial,” Journal of Clinical
Oncology, vol. 20, no. 9, pp. 2240–2250, 2002.
[11] L. H. Sobin and C. Wittekind, Eds., TNM Classification of
Malignant Tumors, Wiley and Sons, New York, NY, USA, 2002.
[12] P. Carlini, P. Papaldo, A. Fabi et al., “Liver toxicity after treat-
ment with gefitinib and anastrozole: drug-drug interactions
through cytochrome p450?” Journal of Clinical Oncology, vol.
24, no. 35, pp. e60–e61, 2006.
[13] C. Ho, J. Davis, F. Anderson, G. Bebb, and N. Murray, “Side
effects related to cancer treatment: case 1. Hepatitis following
treatment with gefitinib,” Journal of Clinical Oncology, vol. 23,
no. 33, pp. 8531–8533, 2005.
[14] S. Tomisaki, T. Takenaka, G. Morizono, T. Tanaka, N.
Momosaki, and F. Inoue, “Successful gefitinib every other day
administration in an advanced lung cancer patient with brain
metastasis after γ knife radiotherapy and chemotherapy,” Gan
To Kagaku Ryoho, vol. 36, no. 13, pp. 2607–2610, 2009.
[15] N. Seki, K. Uematsu, R. Shibakuki, and K. Eguchi, “Promising
new treatment schedule for gefitinib responders after severe
hepatotoxicity with daily administration,” Journal of Clinical
Oncology, vol. 24, no. 19, pp. 3213–3215, 2006.
[16] T. Mitsudomi, S. Morita, Y. Yatabe et al., “Gefitinib versus
cisplatin plus docetaxel in patients with non-small-cell lung
cancer harbouring mutations of the epidermal growth factor
receptor (WJTOG3405): an open label, randomised phase 3
trial,” The Lancet Oncology, vol. 11, no. 2, pp. 121–128, 2010.
[17] H. Satoh, A. Inoue, K. Kobayashi et al., “Low-dose gefitinib
treatment for patients with advanced non-small cell lung
cancer harboring sensitive epidermal growth factor receptor
mutations,” Journal of Thoracic Oncology, vol. 6, no. 8, pp.
1413–1417, 2011.
[18] C. Zhou, Y. L. Wu, G. Chen et al., “Erlotinib versus chemother-
apy as first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): a multicentre, open-label, randomised, phase
3 study,” The Lancet Oncology, vol. 12, no. 8, pp. 735–742,
2011.
[19] M. Scheffler, P. di Gion, O. Doroshyenko, J. Wolf, and U. Fuhr,
“Clinical pharmacokinetics of tyrosine kinase inhibitors: focus
on 4-anilinoquinazolines,” Clinical Pharmacokinetics, vol. 50,
no. 6, pp. 371–403, 2011.
[20] M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of
gefitinib, an inhibitor of the epidermal growth factor receptor
tyrosine kinase, in symptomatic patients with non-small cell
lung cancer: a randomized trial,” The Journal of the American
Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003.
[21] M. Takeda, I. Okamoto, M. Fukuoka, and K. Nakagawa,
“Successful treatment with erlotinib after gefitinib-related
severe hepatotoxicity,” Journal of Clinical Oncology, vol. 28, no.
17, pp. e273–e274, 2010.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
